Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Adva and Autolomous Launch Digital Pioneer Program for Cell Therapy | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Adva and Autolomous Launch Digital Pioneer Program for Cell Therapy

Will co-lead an early adopter initiative focused on digitizing, decentralizing, and scaling out autologous cell therapy manufacturing.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Adva Biotechnology Ltd. and Autolomous Ltd. have joined forces to co-lead the Digital Pioneer Program, an early adopter initiative focused on digitizing, decentralizing, and scaling out autologous cell therapy manufacturing.

The program brings together Adva’s automated and closed-system manufacturing platform with Autolomous’ digital orchestration and manufacturing management technologies, forming an integrated solution designed to assure right-first-time production processes are developed with full data traceability and compliance, thereby reducing overall time-to-patient of life-saving therapies.

“Through the Digital Pioneer Program, we are inviting cell therapy developers to experience the real-world benefits of a unified, intelligent manufacturing model,” said Dr. Ohad Karnieli, Founder and CEO of Adva Biotechnology. “This collaboration is about enabling a new standard—one where automation, digital traceability, and scalability are built into the therapeutic lifecycle from day one.”

“Our mission is simple: to bring life-saving therapies to all patients around the world, safer, faster, and affordable. By providing a digital-first infrastructure to the industry, we are removing the barriers between innovation and the patient,” said Alexander Seyf, Co-Founder and CEO of Autolomous. “This program is a call to action, offering a foundation that will help us build the future of personalized medicine – one defined by trust, equity, and most importantly, acting for hope.”

The Digital Pioneer Program is now open for inquiries from cell therapy developers interested in adopting next-generation manufacturing technologies.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics